FEC-T方案治疗高危乳腺癌患者的疗效研究

Clinical Study of FEC-T Chemotherapy for Treatment of Patients with High-risk Breast Cancer

目的研究3周FEC序贯3周多西他赛与6周期FEC化疗方案对高危乳腺癌的疗效和安全性。方法中平能化医疗集团总医院自2004年1月—2006年1月术后确诊126例高危乳腺癌患者,随机分为两组。一组给予FEC6周化疗,另一组给予3周FEC序贯3周多西他赛化疗,观察其疗效与安全性。结果 126例患者平均随访63个月,FEC组5年DFS为74.2%,OS为86.8%,FEC-T组5年DFS为79.2%,OS为90.8%。结论在高危乳腺癌患者中,三周FEC序贯三周多西他赛在无病生存及总生存方面优于六周FEC。

Objective To investigate the clinical efficacy and safety of sequential FEC three weeks docetaxel and FEC chemotherapy for six cycles to high - risk breast cancer. Methods The confirmed 126 cases of high - risk breast cancer patients from January 2004 to January 2006 at our hospital were randomly divided into two groups. One group was received six weeks of FEC chemotherapy, and the other group was given three weeks FEC sequential docetaxel chemotherapy three weeks to evaluate efficacy and safety. Results 126 cases were followed up for the average 63 months. 5 - year DFS was 74. 2%, OSwas86.8% inFEC group. 5-yearDFS was 79.2%, OS was 90. 8% in FEC-T group. Conclusion In the high - risk breast cancer patients, three weeks FEC sequential three weeks docetaxel was better than six weeks FEC in disease -free survival and overall survival .